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It  is  well  established  that  the  experimental  tumors  induced  in  the  mouse  by 
oncogenic viruses and the majority of those induced by polycyclic hydrocarbons such 
as methylcholanthrene carry tumor-specific transplantation  antigens  (1-4).  In most 
experiments, transplantation immunogenicity could be demonstrated on the basis of 
increased  resistance  against  tumor  cell  challenge  by  animals  that  had  previously 
received cells of the same tumor, either as irradiated cells, as living cells at subthreshold 
doses, or as living cells that were later eliminated by ligation or resection of the tumor. 
On the contrary, no immune rejection response appeared to be elicited by spontaneous 
mouse tumors, i.e.  tumors arising without  experimental intervention  (2,  5).  Similar 
results have been obtained with spontaneous rat tumors (6). 
We  have reported  that,  by treating  a  variety of mouse  tumor  cell  lines  with  a 
mutagen, it is possible to obtain at high frequency stable tumor cell variants (turn-) a 
that fail to form tumors in syngeneic mice. These turn- variants elicit a strong immune 
rejection  response  (7).  They  have been  obtained  from teratocarcinoma  OTT6050, 
Lewis lung carcinoma, mastocytoma P815, and a thymic leukemia (8-10). Most tum- 
variants carry new antigens that are specific for each variant. These antigens can be 
detected  either  in  vivo  by  protection  experiments  or  in  vitro  with  cytolytic  T 
lymphocytes (CTL) (11-14). In rejecting tum- variants, syngeneic mice often acquire 
a  resistance against challenge with the original tumor cell line (tum+). This has been 
observed  with  weakly  immunogenic  tumors  like  Lewis  lung  carcinoma  or  P815 
mastocytoma. More remarkably, it  has also been observed with  a  teratocarcinoma 
cell  line, even though  no protection  was conferred by injection  of irradiated  turn ÷ 
cells or by subcutaneous injection of living cells followed by surgical removal of the 
tumor (11, 15). Recently, a similar observation was made with a radioinduced thymic 
leukemia for which  no protection was observed after immunization with irradiated 
cells  (10).  For both  the teratocarcinoma and the thymic leukemia, protection  after 
immunization with turn- variants was observed not only against a challenge with the 
turn + cell line but also against the original transplantable tumor, indicating that the 
target antigens do not represent tissue-culture artefacts. 
Since  the  use of turn-  variants  appears to  extend  the  class  of tumors  on  which 
x Abbreviations used in this paper: CTL, cytolytic  T lymphocyte;  CTL-P, cytolytic  T lymphocyte  precursor; 
FCS, fetal calf serum; i.p., intraperitoneally; LEB, leukemia I;  LEC, leukemia IV;  MLTC,  mixed 
lymphocyte-tumor  cell culture; turn-, with reduced ability to produce tumors; turn  +, forming progressive 
tumors. 
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specific  transplantation  antigens  can  be  detected,  it  is  important  both  from  a 
fundamental  point  of view  and  from  that  of tumor  immunotherapy  to  find  out 
whether such antigens can be detected by this method on spontaneous tumors, which 
on the basis of previous experimentation appear least likely to carry them. This should 
be done  in conditions that  minimize the possibility of artefactual  antigenicity. We 
choose to  examine two  spontaneous  leukemias obtained by H.  Hewitt  in  CBA/Ht 
mice  (reference  16  and  personal  communication).  These  leukemias  had  not  been 
adapted  to  culture  and  had  always  been  transplanted  in  a  carefully  maintained 
inbred  colony.  We  show  here  that  turn-  variants  could  be  obtained  from  both 
leukemias. Immunization of CBA/Ht  mice with these variants conferred protection 
against the parental tumor and ability to generate cytolytic T  cells specific for that 
tumor. 
Materials  and  Methods 
Mice.  CBA/Ht mice were received from the inbred colony of H. Hewitt. Male or female 
animals of 12-15 wk were used. 
Tumor Cells.  Spontaneous leukemias I  (16) and IV were obtained and generously given to 
us by Dr. H. Hewitt. Both leukemias were maintained by in vivo transfer of tumor cells found 
in the liver in CBA/Ht mice. Leukemias I and IV had been transplanted in CBA/Ht mice 340 
and 205  times respectively before being adapted to culture. We redefined leukemia I as LEB 
and leukemia IV as LEG. Thymic leukemia TH was obtained by H. Hewitt in a mouse that 
had previously received gamma irradiation (5,  10). 
Culture Conditions.  LEB cells were cultured in petri dishes, in RPMI  1640 medium (Gibco 
Laboratories, Grand Island, NY) supplemented with 10 mM Hepes, 1.5 mM L-glutamine, 10% 
fetal calf serum, and 50 #M 2-mercaptoethanol. LEC cells were cultured in tissue culture dishes, 
in DME medium (n  ° 1600; Gibco Laboratories) supplemented with 10 mM Hepes, r-glutamine 
(216  rag/l),  L-asparagine  (36  mg/1),  L-arginine-HCl  (116  mg/1),  glucose  (4.5  mg/i  final 
concentration), 50 #M 2-mercaptoethanol, and  10% fetal calf serum. Both cells were cultured 
in 5% CCh. 
Mutagenesis and Cloning.  Tumor cells were incubated with the mutagen N-methyl-N'-nitro- 
N-nitrosoguanidine at  37°C  in Earle's medium  (7).  After removal of the mutagen, the cells 
were incubated in normal medium for at least 8 d before they were cloned or treated a second 
time with the mutagen. The number of survivor cells was estimated by comparing the number 
of cells present in these cultures 8  d  after mutagenesis to that  of control cultures, that  had 
received parallel treatment without mutagen. At that time the cells were cloned by distributing 
them in limiting dilution conditions in 96-well microplates. LEB cells, which grow in suspension, 
were  distributed  in  round  bottom  microplates  (NUNC  1-63320)  in  thymocyte-conditioned 
medium prepared by incubating CBA/Ht thymus cells (4 ×  106/ml) for 24 h at 37°C in RPMI 
medium containing 10 mM Hepes, 1.5 mM L-glutamine, 50/~M 2-mercaptoethanol, 30% fetal 
calf serum.  LEC cells, which adhere to tissue culture plastic, were distributed in flat bottom 
microplates (Falcon 3040; Falcon Labware, Oxnard, CA) in the normal culture medium except 
that  30%  fetal calf serum  was  added.  Clones were collected from  dilutions yielding <20% 
positive wells. 
Immunization and Challenge.  Cells were resuspended in medium containing 1% fetal calf serum 
and were injected intraperitoneally into CBA/Ht mice. The challenge was carried out intra- 
peritoneally 1-2 mo after immunization. Mice still alive 70 d after the challenge were considered 
negative. 
Mixed Lymphocyte Tumor Cell Cultures.  Spleen cells (3  ×  10 7)  from immune CBA/Ht  mice 
were stimulated with 3 ×  105 irradiated LEB or LEC cells (5,000 rads gamma irradiation). The 
stimulation was performed in  10  ml of the medium used for the culture of LEC  described 
above, except that fetal calf serum was replaced by 0.2% CBA/Ht serum. Cytolytic activity was 
measured after 6 d by chromium release as described before (12). Percent specific release =  100 
×  (experimental release -  spontaneous release)/(maximum release -  spontaneous release). The 
spontaneous release was lower than 20% of the label incorporated into the cells. 1994  IMMUNOGENIC VARIANTS OF SPONTANEOUS  MOUSE LEUKEMIAS 
Limiting Dilution Stimulation and Expansion of CTL Clone.  CBA/Ht mice were injected intra- 
peritoneally (i.p.)  with  106 living LEC30 cells. 35 d later, these mice were boosted i.p.  with 3 
×  106 irradiated (5,000 rads) LEC30 or LEC1 cells. 5 d later, the peritoneal exudate cells were 
collected and  limiting  numbers  (10-100)  of these cells  were stimulated  with  103 irradiated 
(5,000  rads)  LEC30 or LEC1 cells in the presence of 108 irradiated  syngeneie spleen cells as 
feeder cells  in 200 #1 of medium containing secondary allogeneic mixed lymphocyte culture 
supernatant as a source of T  cell growth factor (13). Aliquots of 150 #1 of microcultures lysing 
specifically LEC30 or LEC cells were transferred to 1 ml of  culture containing 5 ×  10  n irradiated 
syngeneic spleen cells, 105 irradiated LEC30 or LEG 1 cells and secondary allogeneic supernatant 
(13). For subsequent passages (every 5-8 d), 5 ×  104 cells were transferred to similar cultures. 
Results 
Isolation of tum-  Variants.  Spontaneous  transplantable  leukemias  LEB  and  LEC 
were adapted  to culture and clonal cell lines LEB 1 and LEC 1 were obtained.  LEB 1 
produced  progressive tumors  in >95%  of the CBA/Ht  mice that  received  an  intra- 
peritoneal injection of 300 cells. It was found to express the Thy 1.2 antigen, indicating 
that LEB is a T  cell leukemia. LEC appears to be a B cell leukemia, since surface IgM 
was  found on clonal line  LEC1.  100 cells of this  clone regularly produce tumors  in 
>95% of the syngeneic mice. 
LEB1  and  LEC1  cultures  were  treated  with  the  mutagen  N-methyl-N'-nitro-N- 
nitrosoguanidine  (MNNG)  at a  concentration of 3 ~tg/ml for a  time varying from 20 
to  40  min  so  as  to  obtain  mutagenized  populations  in  which  cell  survival  was 
approximately  equal  to  0.5%.  After  a  period  of cell  multiplication  of  15  d,  these 
populations  were  submitted  to  a  second  round  of mutagenesis  under  the  same 
conditions and 8 d later populations with a survival rate of ~0.5% were cloned. From 
49 mutagenized clones derived from LEB 1, 5 failed to form tumors in most CBA/Ht 
mice even when  injected  at  a  dose of 105 cells,  that  is,  >300  times  the  tumorigenic 
dose of LEB1. No such tum- variant had been found among 27 clones isolated from 
the LEB 1 population mutagenized only once. For LEC 1, 41 clones were isolated after 
two  rounds  of mutagenesis.  Four  turn-  clones  were  found  that  formed  progressive 
tumors in fewer than  10% of the mice after injection of 105 cells. Representative results 
obtained with tum÷ and tum- cells derived from LEB and LEC are shown in Table 
I. 
As observed previously in other tumor systems (7-9), LEB and LEC turn- variants 
formed tumors in mice that had received 580 rads of gamma radiation,  a  sublethal 
immunosuppressive dose (Table I). In vitro growth kinetics of the tum- variants were 
very similar to those of the parental  LEB 1 and LEC 1 lines. 
Protection Against the Original Tumors.  In agreement with the observations of Hewitt 
on  spontaneous  mouse  tumors  (5),  we  did  not  observe  any  resistance  against  a 
challenge with LEB 1 or LEC 1 in mice that had received  1 mo earlier a  large number 
of the corresponding irradiated cells (Table II). However, mice that had been injected 
with living cells from turn- variants derived from LEB or LEC and had rejected these 
cells, were found to be largely resistant  to a  challenge with  the corresponding turn ÷ 
cell  line.  The  results  shown  in  Table  II were confirmed  in  other  experiments.  The 
protection  by variant  LEC37  shown  in  Table  II was  rather  weak  since 67%  of the 
mice  formed  tumors.  However,  tumor  formation  in  those  mice  was  considerably 
retarded  with  respect  to the  controls  and  in  another  experiment  involving animals 
immunized  with  LEC37  and  challenged  with  LEC1  only  36%  (5/14)  of the  mice 
formed tumors versus  100% (19/19)  in the controls. VAN PEL  ET AL.  1995 
TABLE  I 
Tumors Produced by turn  + and turn- LEB and LEC Cells in CBA/Ht Mice 
Clone*  Cell dose 
No. mice with tumors/No, mice in- 
jected 
Unirradiated  Irradiated 
mice  mice* 
LEB1  (turn +)  300  20/20 (31 d) §  ND 
LEB26  105  0/37  3/3 (26 d) 
LEB28  10  s  (3/16  ND 
104  4/17 (32 d)  3/3 (20 d) 
LEC1 (turn +)  100  19/19 (13 d)  ND 
LEC30  10  s  1/38 (42 d)  2/2 (15 d) 
LEC37  10  s  5/32 (39 d)  3/3 (15 d) 
* Injected i.p. 
* 580  racks of gamma  irradiation  from  a  cesium  source,  given 2  h  before 
injection. 
Mean survival time. 
ND, not determined. 
TABLE  II 
In Vivo Protection Against the Original  Tumor Cell Line 
% Mice with tumor after challenge with 
tum÷ clone:* 
Immunizing  (No. mice with tumors/No, mice in- 
cell*  jected) 
LEB1  LECI 
Irradiated turn +  LEB1  95 (19/20),  d34 §  ND 
Living tum-  LEB15  14 (3/21),  d39  95 (20/21),  d15 
LEB26  29 (6/21), d40  100 (19/19),  d16 
LEB28  37 (7/19),  d41  89 (17/19),  d16 
Irradiated turn  +  LECI  ND  100 (20/20),  d16 
Living turn-  LEC30  86 (12/14),  d40  6 (1/18), d18 
LEC37  100 (10/10),  d41  67 (12/18),  d36 
None  --  100 (30/30),  d34  100 (20/20),  dl5 
* CBA/Ht mice were immunized i.p. either with 5 ×  10  s turn + cells killed by 
gamma  irradiation  (5,000 rads)  or with  10  ~ living cells  of various  turn- 
variants.  Control  mice were injected with  the same  amount  of medium. 
27-32 d later, they were injected i.p. with ceils from turn  + clone LEB1  (3 × 
10  2') or LEC1 (10~). 
* Animals  found  without  tumor  70  d  after  the  challenge were considered 
negative. 
0 Mean survival time. 
The  protection  conferred by the LEB  and  LEC  tum-  variants  appears  specific for 
the parental  tumor cell line. No protection was observed when mice immunized  with 
LEB  rum-  variants  were  challenged  with  LEC1  or  conversely  (Table  II).  Other 
experiments  showed  that  LEB or LEC  turn-  variants  did not  induce  any  protection 
against  syngeneic  T  cell leukemia  TH  or  vice versa  (reference  10  and  unpublished 
results). 
The protection conferred by LEB and LEC  turn-  variants was not limited to turn + 
cells grown  in culture.  Mice immunized  with  LEB26 showed  a  significant  resistance 
against  a  challenge  with  LEB  cells  that  had  been  exclusively transplanted  in  vivo. 1996  IMMUNOGENIC  VARIANTS  OF  SPONTANEOUS  MOUSE  LEUKEMIAS 
Mice immunized  with LEC30  were similarly protected against a  LEC  challenge (Fig. 
1). However,  LEC30  did not induce a  protection against LEB nor did LEB26  protect 
against  LEC  (data not shown). 
Cytolytic  T  Lymphocyte  Response.  Spleen  cells  from  mice  that  had  rejected  LiB  or 
LEC  tum-  variants were stimulated  in vitro with irradiated  cells of the immunizing 
variant. To avoid nonspecific stimulation, the fetal calf serum often used in such tests 
was replaced by a  low concentration  of syngeneic mouse serum. After 6  d, these mixed 
lymphocyte-tumor  cell  cuhures  (MLTC)  were  assayed  for  cytolytic  activity  on  the 
immunizing  tum-  clone,  on  other  clones  derived  from  the same  tumor  line and  on 
ther  syngeneic  tumor  cells  (Tables  III  and  IV).  As  had  been  observed  with  turn- 
variants  derived  from  other tumors  (12,  14),  the cytolytic activity was  higher on the 
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FIG.  1.  Protection against transplantable tumors LEB and LEC. CBA/HI mice were immunized 
intraperitoneally with  106 living cells of turn- variants LEB26 (A) and LEC30  (0). Control mice 
were injected with medium (A and O). After 32 d, the mice were challenged with 60 living LEB 
cells (left) or 40 living LEC cells (right). The challenging cells were obtained from the liver of CBA/ 
Ht mice injected 12 d earlier with tumor cells that had been transferred exclusively in vivo. 20 mice 
were used in each group. 
TABLE  III 
Cytolytic Activity after In  Vitro Stimulation of Spleen Cells  from Mice Immunized with LEB tum- 
Variants 
Spleen cells*  Stimulator cells  E/T* 
Percent specific Cr  5. release from target ceils  § 
LEB1  LEB26  LEB28  LEC1  THI H 
anti-LEB26  LEB26  3:1  26  51  34  3  0 
1:1  14  31  19  1  0 
LEB1  10:1  28  39  37  5  0 
3:1  17  22  23  1  0 
anti-LEB28  LEB28  10:1  7  16  72  2  0 
3:1  4  8  56  0  0 
LEB 1  10:1  14  20  25  5  0 
3:1  8  12  12  l  0 
* CBA/Ht mice were immunized i.p. with 106 living ceils of tum- variants LEB26 and LEB28. After 72 d 
(LEB26)  or 61  d  (LEB28), spleen cells were stimulated with irradiated LEB cells,  for 6 d  in medium 
containing 0.2% CBA/Ht serum. 
* E/T, effector to target cell ratio. 
§ The lytic activity of these effector cells was tested in a 6-h Cr  5~ release assay performed with 5 ×  103 target 
cells in medium containing 10% FCS. 
I TH1 is a clonal line derived from thymic leukemia TH. VAN  PEL  ET  AL.  1997 
TABLE  IV 
Cytolytic Activity after In  Vitro Stimulation of Spleen Cells  from Mice Immunized with LEG turn- 
Variants 
Spleen cells*  Stimulator cells  E/I'* 
Percent specific Cr  sl release from target cells ~ 
LEC1  LEC30  LEC37  LEB1  TH1 
Anti-LEC30  LEC30  90:1  17  47  20  0  0 
30:1  5  29  5  0  0 
10:l  1  18  2  0  0 
LEC 1  90:1  48  46  51  1  0 
30:1  36  32  34  0  0 
10:1  18  20  18  0  0 
Anti-LEC37  LEC37  30:1  36  32  90  2  2 
10:1  19  13  75  0  2 
LEC 1  30:1  46  43  48  2  0 
10:1  26  24  25  I  0 
* CBA/Ht  mice  were immunized  intraperitoneally  with  l0  s  living cells  of tum-  variants  LEC30  and 
LEC37. After 30 d, spleen cells were stimulated with irradiated LEC cells for 6 d in medium containing 
0.2% CBA/Ht serum. 
* E/T, effector to target cell  ratio. 
The lytic activity of these effector cells  was tested in a  4-h Cr  sl  release assay carried out with 5  ×  10  n 
tumor target cells in medium containing 10% FCS. 
immunizing variants than  on other turn- clones or on turn + cells derived  from the 
same tumor,  indicating  the presence of a  new  antigen  specific for the  immunizing 
turn- variant. This was found with the three LEB and the three LEC turn- variants 
that were tested. In addition, a significant cross-reactive lysis was always observed on 
all the targets derived from the same parental tumor as the immunizing cells. When 
the  immune spleen  cells were restimulated  with  the  corresponding  turn ÷ cells,  the 
levels of lytic activity observed on all  the  targets derived  from the parental  tumor 
were approximately equal.  These results confirm those obtained in vivo to indicate 
that syngeneic mice recognize an antigenic determinant on leukemias LEB and LEC. 
These antigens appear to be specific for each tumor since spleen cells immunized and 
restimulated  with  LEB  variants showed  very little activity on  LEC or TH  targets. 
Likewise, spleen cells immunized with LEC variants do not lyse LEB or TH targets. 
The absence of protection observed in  vivo in  mice that  had received irradiated 
LEB or LEC cells was paralleled by the observation that no significant lyric activity 
could be demonstrated after in vitro restimulation of the lymphocytes of these animals 
(data not shown). 
Cytolytic  T  Cell Clones Directed Against LEC.  The specificity of CTL directed against 
LEC cells was also analyzed at the clonal level. Mice immunized with living LEC30 
cells were boosted i.p. with irradiated  LEC30 or LEC 1 cells.  5 d  later, lymphocytes 
from  the  peritoneal  cavity  were  collected  and  restimulated  in  limiting  dilution 
microcultures  with  irradiated  LEC30  or  LEC1  cells  in  medium  containing  T  cell 
growth factor. After 8  d, aliquots  from each microculture were assayed for cytolysis 
against LEC30 and LEC 1. Only microcultures prepared with numbers of responder 
cells resulting in clonal conditions were considered. When the boost and the in vitro 
stimulation  had been performed with LEC30,  the majority of the CTL clones were 
LEC30-specific. The frequency of CTL precursors (CTL-P) present in the peritoneal 
cell populations,  that  were specific for LEC30  was estimated  to be  7.5  ×  10  -s and 1998  IMMUNOGENIC  VARIANTS  OF  SPONTANEOUS  MOUSE  LEUKEMIAS 
that of CTL-P directed against LEC was 2.5 X  10  -3. When LEC1 cells were used as 
booster and stimulator cells, almost all of the positive wells lysed both LEC30  and 
LEC1, and the anti-LEC CTL-P frequency was 2 X  10  -a. 
A number of CTL clones that lysed either LEC30 only or both LEC30 and LEC 1 
were transferred for further clonal expansion in cultures containing irradiated LEC30 
or LEC 1 cells as stimulator cells and T  cell growth factor. The cells were subsequently 
transferred every 5-8  d  under  the  same conditions.  It was possible to expand  and 
maintain for more than  1 mo without loss of specificity or activity CTL clones that 
lysed LEC30 exclusively and others that lysed LEC30 and LEC1 equally well but not 
LEB,  TH, or syngeneic blasts.  Results  obtained with  two representative clones are 
shown in Fig. 2. 
Discussion 
By  mutagen  treatment  we  have  been  able  to  obtain  turn-  variants  from  two 
spontaneous leukemias that were adapted to culture. Three LEB and three LEC turn- 
variants were found to carry new variant-specific antigens that elicited a specific CTL 
response. The frequency of turn- variants obtained with LEB and LEC was somewhat 
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FIo.  2.  Cytolytic activity of long-term CTL clone CTL-LEC30:3, which is specific for the rum- 
antigen of LEC30, and CTL-LECI:2 directed against a  tumor-associated antigen of tumor LEC. 
For  CTL-LEC30:3,  mice  were  immunized  intraperitoneally  with  living  LEC30  ceils,  boosted 
intraperitoneally  with  irradiated  LEC30  ceils,  and  5  d  later  the  peritoneal  lymphocytes were 
collected  and  stimulated  in  limiting  dilution  conditions  with  LEC30.  A  microculture  showing 
specificity  for  LEC30  was  maintained  and  expanded  in  culture  with  LEC30  stimulator  cells 
(Materials and Methods). For CTL-LEC 1:2,  the mice were immunized with LEC30, boosted with 
LECI,  and  the  peritoneal  lymphocytes were  stimulated  with  LECI.  A  microculture  showing 
specificity for LEC was expanded with LEC I as stimulator cells. The assay was performed after the 
clones had been maintained in culture for more than 30 d  following initial transfer from limiting 
dilution  microculture. The cytolytic activity shown here was measured using 2,000  nlCr-labeled 
target cells as follows. LEC30  (O), LEC1  (O), LEB  (A), TH  (A), and syngeneic conconavalin A- 
stimulated lymphoblasts ([3) in a 6-h chromium release assay. VAN  PEL  ET  AL.  1999 
lower  than  that  obtained  by  similar  treatment  of  other  mouse  tumors  such  as 
teratocarcinoma, Lewis lung carcinoma, or mastocytoma P815.  This may be due to 
the highly malignant and metastatic character of these tumors, which are able to kill 
animals rapidly after injection of a  very small number of cells.  It is likely that such 
tumor cells must acquire extremely immunogenic determinants to lose their tumori- 
genicity. Yet, together with our previous observations these results suggest  that  the 
obtainment  at  high  frequency of immunogenic variants after N-methyl-N'-nitro-N- 
nitrosoguanidine  treatment  will  be  generally  applicable  to  mouse  tumors.  Recent 
observations by Frost,  Kerbel,  and  their  associates  (17)  indicate  that  the  mutagen 
ethyl methane sulfonate is  also capable of generating in vitro immunogenic mouse 
tumor cell variants. 
The protection conferred by LEB or LEC-derived turn- cells against the correspond- 
ing turn + cell line demonstrates that these spontaneous tumors carry tumor-associated 
transplantation  antigens  that  are the targets of a  syngeneic rejection response. The 
absence of cross-protection between LEB and LEC shows that each of these tumors 
carries a different antigen. We also reported that mice immunized with turn- variants 
derived  from syngeneic leukemia TH  were not  protected  against  a  challenge  with 
LEB cells (10).  The patterns of T  cell cytolytic activity observed in animals that have 
rejected  turn-  variants  confirm  the  view  that  LEB,  LEC,  and  TH  each  carry  a 
different tumor-associated antigen. 
Since a  protection was observed against the transplantable LEB and LEC tumors 
that  had  never been  passaged  in  vitro,  the  relevant  tumor-associated  antigens  are 
certainly not tissue-culture artefacts. It is also improbable that these antigens represent 
minor  histocompatibility  differences  between  the  primary  tumor-bearers  and  the 
presently available CBA/Ht mice as such antigens would be expected to be common 
to these  tumors.  Even though  it  is  impossible to exclude  that  these  antigens  arose 
during evolution of the tumors in the course of their multiple transplantations,  our 
observations raise the possibility that at least some primary spontaneous mouse tumors 
carry tumor-specific transplantation  antigens.  These results by no means contradict 
the  well-established  contrast  between  the  immunogenicity  observed  on  virus-  or 
carcinogen-induced tumors and the lack of it on spontaneous tumors. However, they 
indicate  that  this  antigenic  difference  may not  be  an  absolute  one  and  that  the 
immunogenicity of weak determinants can be notably increased by interaction with 
artificially added new determinants, a  possibility that has previously been suggested 
and demonstrated by others (18-20). 
Since the use of turn- variants appears to extend notably the class of mouse tumors 
in  which  transplantation  antigens  can  be  detected,  our  results  provide  a  strong 
incentive to examine whether similar variants, carrying new antigens  detectable by 
autologous CTL, can be obtained from human tumor cells. Such variants may permit 
the demonstration  of tumor-associated  transplantation  antigens  on human  tumors. 
Then,  the possibility of using turn-  variants to induce  a  rejection  response against 
human tumors could be cautiously considered. 
Summary 
Two spontaneous  mouse  leukemias were  adapted  to  culture.  In  agreement  with 
most reported observations on spontaneous tumors, injection of irradiated cells of the 
malignant culture cell lines failed to protect mice against these leukemias. These cell 2000  IMMUNOGENIC VARIANTS OF SPONTANEOUS  MOUSE LEUKEMIAS 
lines were treated  in vitro with  the  mutagen  N-methyl-N'-nitro-N-nitrosoguanidine 
and stable immunogenic variants (turn-) were obtained, that failed to form progressive 
tumors in syngeneic CBA/Ht  mice.  Mice that had rejected tum- variants showed a 
significant degree of resistance to challenge not only with the original malignant cell 
line  but  also  with  the  original  transplantable  tumor.  No  protection  was  observed 
against  syngeneic tumor cells other than  those of the parental  tumor.  These results 
indicate that these two spontaneous leukemias carry a specific transplantation antigen 
that can be the target of a  rejection response by syngeneic mice.  In confirmation of 
this,  we found that  lymphocytes of CBA/Ht  mice that  had  rejected  tum-  variants 
could be restimulated  in vitro so as to develop a cytolytic activity directed against an 
antigen that was specific for the original tumor cell line. 
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